Remote Monitoring Next Front For Regulatory Flexibility, But Will Some Accelerated Approvals Ever Be Confirmed?
Executive Summary
Former OTAT Director Wilson Bryan says rare disease development will advance thanks to remote monitoring tools, but questions whether the long times needed to confirm clinical benefit for some drugs or biologics could come at the expense of better products.